Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Matei D, Enserro D, Randall M, Mutch D, Small W, DiSilvestro P, Spirtos N, O’Malley D, Cantuaria G, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland F, Warshal D, Bonebrake A, Tewari K, Tan A, Powell M, Walker J, Santin A, Kim J, Miller D. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. Journal Of Clinical Oncology 2024, 43: 1055-1060. PMID: 39700442, PMCID: PMC11908887, DOI: 10.1200/jco.24.01121.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRandomized phase III trialOverall survivalC-RTFederation of Gynecology and Obstetrics (FIGOInternational Federation of Gynecology and Obstetrics (FIGOFollow-upIncreased recurrence-free survivalLocally advanced endometrial cancerLocally advanced endometrial carcinomaRate of local recurrenceLymph-vascular space invasionLong-term follow-upGross residual diseaseStratified hazard ratioProbability of OSAdvanced endometrial cancerMedian Follow-UpAdvanced endometrial carcinomaKaplan-Meier methodPhase III trialsBody mass indexMedian OSOS benefitPositive cytology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply